127 related articles for article (PubMed ID: 37770809)
1. Correction: Overview of the current use of levosimendan in France: a prospective observational cohort study.
Cholley B; Bojan M; Guillon B; Besnier E; Mattei M; Levy B; Ouattara A; Tafer N; Delmas C; Tonon D; Rozec B; Fellahi JL; Lim P; Labaste F; Roubille F; Caruba T; Mauriat P;
Ann Intensive Care; 2023 Sep; 13(1):94. PubMed ID: 37770809
[No Abstract] [Full Text] [Related]
2. Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis.
Guilherme E; Jacquet-Lagrèze M; Pozzi M; Achana F; Armoiry X; Fellahi JL
Crit Care; 2020 Jul; 24(1):442. PubMed ID: 32677985
[TBL] [Abstract][Full Text] [Related]
3. The evaluation of levosimendan in patients with acute myocardial infarction related ventricular septal rupture undergoing cardiac surgery: a prospective observational cohort study with propensity score analysis.
Li ZS; Wang K; Pan T; Sun YH; Liu C; Cheng YQ; Zhang H; Zhang HT; Wang DJ; Chen ZJ
BMC Anesthesiol; 2022 May; 22(1):135. PubMed ID: 35501683
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
[TBL] [Abstract][Full Text] [Related]
5. The Use of Levosimendan after Out-of-Hospital Cardiac Arrest and Its Association with Outcome-An Observational Study.
Rysz S; Fagerlund MJ; Lundberg J; Ringh M; Hollenberg J; Lindgren M; Jonsson M; Djärv T; Nordberg P
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566747
[TBL] [Abstract][Full Text] [Related]
6. Successful use of levosimendan as a primary inotrope in pediatric cardiac surgery: An observational study in 110 patients.
Joshi RK; Aggarwal N; Aggarwal M; Pandey R; Dinand V; Joshi R
Ann Pediatr Cardiol; 2016; 9(1):9-15. PubMed ID: 27011685
[TBL] [Abstract][Full Text] [Related]
7. Prospective observational study of levosimendan and weaning of difficult-to-wean ventilator dependent intensive care patients.
Sterba M; Banerjee A; Mudaliar Y
Crit Care Resusc; 2008 Sep; 10(3):182-6. PubMed ID: 18798715
[TBL] [Abstract][Full Text] [Related]
8. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study.
Hasslacher J; Bijuklic K; Bertocchi C; Kountchev J; Bellmann R; Dunzendorfer S; Joannidis M
Crit Care; 2011 Jul; 15(4):R166. PubMed ID: 21749676
[TBL] [Abstract][Full Text] [Related]
9. Renal effects of levosimendan: a consensus report.
Yilmaz MB; Grossini E; Silva Cardoso JC; Édes I; Fedele F; Pollesello P; Kivikko M; Harjola VP; Hasslacher J; Mebazaa A; Morelli A; le Noble J; Oldner A; Oulego Erroz I; Parissis JT; Parkhomenko A; Poelzl G; Rehberg S; Ricksten SE; Rodríguez Fernández LM; Salmenperä M; Singer M; Treskatsch S; Vrtovec B; Wikström G
Cardiovasc Drugs Ther; 2013 Dec; 27(6):581-90. PubMed ID: 23929366
[TBL] [Abstract][Full Text] [Related]
10. Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data.
Massol J; Simon-Tillaux N; Tohme J; Hariri G; Dureau P; Duceau B; Belin L; Hajage D; De Rycke Y; Charfeddine A; Lebreton G; Combes A; Bouglé A
Crit Care; 2023 Feb; 27(1):51. PubMed ID: 36750852
[TBL] [Abstract][Full Text] [Related]
11. Short-term effects of levosimendan use for venoarterial extracorporeal membrane oxygenation: A systematic review and meta-analysis.
Yang B; Zhao T; Guo B; Li Y
Perfusion; 2023 Mar; 38(2):305-312. PubMed ID: 34689640
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of levosimendan as treatment option in a large case-series of preterm infants with cardiac dysfunction and pulmonary hypertension.
Schroeder L; Holcher S; Leyens J; Geipel A; Strizek B; Dresbach T; Mueller A; Kipfmueller F
Eur J Pediatr; 2023 Jul; 182(7):3165-3174. PubMed ID: 37100959
[TBL] [Abstract][Full Text] [Related]
13. Multicenter experiences with levosimendan therapy and its safety in patients with decompensated advanced heart failure.
Lelonek M; Stopczyńska I; Korościk E; Straburzyńska-Migaj E; Gruchała M
Adv Clin Exp Med; 2020 Nov; 29(11):1305-1312. PubMed ID: 33269816
[TBL] [Abstract][Full Text] [Related]
14. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
15. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
[TBL] [Abstract][Full Text] [Related]
16. Influence of timing of Levosimendan administration on outcomes in cardiac surgery.
Schiefenhövel F; Berger C; Penkova L; Grubitzsch H; Haller B; Meyer A; Heringlake M; Sander M; Erb JM; Balzer F; Treskatsch S
Front Cardiovasc Med; 2023; 10():1213696. PubMed ID: 37564910
[TBL] [Abstract][Full Text] [Related]
17. Impact of levosimendan on efficacy and renal function in acute heart failure according to renal function: A perspective, multi-center, real-world registry.
Zhang H; Jiang L; Fu R; Qin P; Zhang X; Tian T; Feng GX; Yang YM
Front Cardiovasc Med; 2022; 9():986039. PubMed ID: 36337876
[TBL] [Abstract][Full Text] [Related]
18. The use of the novel calcium sensitizer levosimendan in critically ill patients.
Plöchl W; Rajek A
Anaesth Intensive Care; 2004 Aug; 32(4):471-5. PubMed ID: 15675206
[TBL] [Abstract][Full Text] [Related]
19. Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design.
Tycińska A; Gierlotka M; Bartuś S; Gąsior M; Główczyńska R; Grześk G; Jaguszewski M; Kasprzak JD; Kubica J; Legutko J; Leszek P; Nessler J; Pacileo G; Ponikowski P; Sobkowicz B; Stępińska J; Straburzyńska-Migaj E; Wojakowski W; Zawiślak B; Zymliński R;
Adv Med Sci; 2022 Mar; 67(1):18-22. PubMed ID: 34656873
[TBL] [Abstract][Full Text] [Related]
20. Levosimendan or Milrinone for Ventricular Septal Defect Repair With Pulmonary Arterial Hypertension.
Nag P; Chowdhury SR; Behera SK; Das M; Narayan P
J Cardiothorac Vasc Anesth; 2023 Jun; 37(6):972-979. PubMed ID: 36906394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
